Autologous stem cell transplantation (ASCT) is a new treatment option in patients with systemic AL amyloidosis (AL). The purpose of this review is to summarize the clinical experience of ASCT for AL, and to discuss the feasibility and the future developments of this new approach.
Introduction
Primary systemic amyloidosis (AL) is a plasma cell dyscrasia characterized by deposits of fibrillar aggregates of monoclonal immunoglobulin light chains in vital organs. 1 Despite the use of oral melphalan and prednisone (MP) the median survival is still only 17 to 18 months. 2 Based on the success of highdose therapy (HDT) followed by autologous stem cell transplantation (ASCT) in multiple myeloma (MM), 3, 4 a malignant plasma cell dyscrasia, ASCT has been used to treat AL. Preliminary reports have shown that some patients have experienced considerable clinical improvement of their disease after HDT and ASCT. [5] [6] [7] Some authors suggest that this concept which may represent an important therapeutic advance in the treatment of this rapidly fatal disease should be systematically considered in patients with evolutive AL disease. 5, 8 However, until now less than 100 cases of ASCT for AL have been reported in regular manuscripts. The purpose of this review is to summarize the clinical experience of ASCT for AL, and to discuss the feasibility and the future developments of this new approach.
Clinical experience of ASCT for AL
Although the concept of a relationship between dose of chemotherapy and response to treatment has been clearly established in MM in the 1980s, the use of HDT in AL has been evaluated only recently. The first series of HDT and ASCT for AL was reported by Comenzo et al in 1996. 9 This preliminary report included five patients, never pretreated, younger than 61 years with adequate cardiac, pulmonary, hepatic and renal function at the time of transplantation. Clinical presentations included nephrotic syndrome in one, hepatomegaly in one, symptomatic cardiomyopathy in one and gastrointestinal involvement with polyneuropathy in two patients. Hematopoietic progenitor cells were mobilized with granulocyte colony-stimulating factor (G-CSF) alone. The conditioning regimen consisted of high-dose i.v. melphalan 200 mg/m 2 (HDM200). The procedure was tolerable and no toxic death occurred. In each case, with a follow-up superior 10 Half of the patients never received any conventional chemotherapy before HDT. Patients were classified according to their predominant organ involvement: renal, cardiac, or other (neuropathic, hepatic or lymphatic). The 3-month treatment-related mortality rate was similar in both groups, 15% and 17% for HDM and IDM, respectively. In both groups the survival at 4 years was related to the predominant site of the disease: 83% with HDM and 75% with IDM in case of renal disease, 33% with HDM and 37% with IDM for patients with cardiac AL. The rates of complete hematologic response and of objective clinical improvement were higher in the group of patients treated with HDM 55% and 54%, respectively, compared with 38% and 29% in the group of patients treated with IDM. Remarkably, some patients with neuropathy and cardiac symptoms experienced clinical improvement. These impressive results lead their authors to conclude that HDT and ASCT could be considered standard therapy for patients with AL who meet functional criteria for ASCT. This is the critical issue of such a strategy. The results of ASCT that seem to be substantially better than those obtained with conventional oral chemotherapy concern a selected population of patients. Three other retrospective studies of ASCT 6, 11, 12 and one study of prognostic factors for survival of 234 patients with AL treated at the Mayo Clinic functionally eligible for ASCT 13 highlight the potential bias in the analysis of a one center experience of selected patients. In a multicentric retrospective trial, Moreau et al 6 have analyzed all cases of ASCT performed for AL in the French Myeloma Study Group IFM before 1997. Twenty-one cases were studied. Even if the 57% actuarial 4-year survival was encouraging, the feasibility of the procedure in this 'historical' series was bad. The toxic death rate was 40% with nine deaths observed within the first month following ASCT due to multi-organ failure, cardiac arrhythmia or severe bleeding. On the contrary, in patients surviving the treatment procedure the response rate was high (83%) with improved organ function in the predominant sites of involvement, mainly cardiac and renal. Overall, the actuarial 4-year event-free survival (EFS) was 30%. The univariate analysis of prognostic factors showed that the only parameter predictive for both overall survival (OS) and EFS was the number of clinical manifestations at the time of ASCT. When patients had fewer than two clinical manifestations at the time of ASCT, the 4-year OS and EFS were 91.7% and 46.3%, respectively, compared with 11.1% for both parameters when two or more major clinical manifestations were documented before ASCT.
One can argue that these toxicity results are the worst ever reported in a series of ASCT. This might be due to the little experience of centers regarding the 'specific morbidity' related to AL, with unusual gastrointestinal (GI) bleeding, sudden cardiac events, multiorgan failure or risk of renal insufficiency. 5, 6, 11, 12 These patients are different from myeloma patients in whom the risk of toxic death after ASCT is less than 5%. 3, 4 The organ damage caused by amyloid deposition with renal, cardiac, liver, GI or neurological involvement are difficult to evaluate 1, 7, 14 and probably highly underestimated at the time of ASCT.
Two other one center retrospective experiences have confirmed that ASCT carried a much higher risk of morbidity and mortality than transplantation for myeloma. Gillmore et al 11 and Gertz et al 12 have reported 40 and 22 cases of transplantation for AL with 37.5 and 21% transplant-related mortality, respectively. In these two studies, the response rate among the patients who survived the treatment procedure was encouragingly high, 72 and 70% respectively.
Selection criteria for ASCT
In these series, as well as in the French or Boston group experience, neither the number nor the outcome of patients with similar ages treated for AL during the same period and not transplanted due to clinical status or physician choice are stated. Moreover, the outcome of patients eligible for transplantation according to their good performance status and to adequate cardiac, pulmonary, hepatic or renal function who should not be autografted but treated with MP is not known. This question was raised in a recent trial performed at the Mayo Clinic. 13 The authors have queried the Mayo Clinic amyloid database for all patients with AL seen from 1983 to 1997 who would have been eligible for ASCT but who were not transplanted. From the 1288 patients seen during this period, 234 met eligibility criteria for ASCT which were the following: age less than 71 years, biopsy-proven AL, symptomatic disease, and adequate cardiac, pulmonary, hepatic or renal function. The median survival of this subgroup of 234 patients with AL was 45.6 months, 60.6 months for individuals less than 50, 46.3 months for individuals between 51 and 60, and 30.2 months for patients between 61 and 70 years. The outcome of this good risk population is very different from what is reported for the 'average amyloid patient' treated with standard oral chemotherapy with a median survival of 13-24 months. 2, 15 The authors concluded that eligibility for ASCT was an independent favorable prognostic factor for AL, and that a randomized clinical trial evaluating ASCT vs standard chemotherapy was indicated in this subgroup of patients.
Other questions are under evaluation. What is the best source of stem cells? What is the best conditioning regimen? Should patients receive 'debulking' chemotherapy before the procedure of ASCT?
Source of stem cells
Most physicians involved in transplant programs for AL have chosen myeloid-growth factor mobilized peripheral blood stem cells (PBSC) as support for transplantation. As is true in other settings, hematopoietic engraftment is more rapidly achieved with PBSC than after autologous bone marrow grafting. 9 Some authors consider that cyclophosphamide-or other myelosuppressive chemotherapy-based mobilization regimens, and their potential infectious and myocardial side-effects are too risky. 5, 16 Deaths during the mobilization period have been reported after the use of cyclophosphamide for PBSC mobilization from rapid atrial fibrillation or progressive heart failure. 17 Comenzo et al 16 have tested two different mobilization regimens with sequential GM + G-CSF or G-CSF alone and found that both were equally useful. In this trial, a morbidity rate of 17% was reported due to acute pulmonary edema in one case and thrombotic complications in four cases. Of note, toxicity was related not only to mobilization but also to leukapheresis. In this latter series, stem cell collection was stopped after two leukaphereses due to weight gain, worsening edema and decreased room air oxygen saturation. Lefrère et al 18 also reported two sudden deaths during the procedure of leukapheresis itself due to arrhythmia in patients with clinical symptoms of congestive heart failure before the collection. Concerns about tumor cell contamination in stem cell preparations has led to the use of CD34
+ cell selection as a means of purging. The group at Boston University has reported a trial of CD34 + cell selection in patients with AL undergoing ASCT after HDM200. 19 Patient-specific oligonucleotide primers were designed to evaluate stem cell collection contamination at the molecular level. Contamination was found in collections from four to seven patients. CD34
+ selection was always feasible, with adequate doses of CD34 + cells in the selected grafts. All patients achieved rapid platelet recovery but delayed lymphocyte recovery. The efficacy of CD34 + cell selection and its impact upon OS and EFS remains to be evaluated.
Conditioning regimen
The best conditioning regimen for AL remains to be determined. Most physicians are using HDM200 before ASCT. 5, 6, 11 In a small series of 10 patients, Saba et al 17 have considered that the use of TBI was too toxic with a higher risk of cardiorespiratory events. In order to reduce toxicity, Comenzo et al 10 have proposed a reduced dose of melphalan: 100 or 140 mg/m 2 in patients older than 60 or patients with diminished cardiac or renal function. In this situation, as mentioned above, the 3-month treatment-related mortality was not different compared with HDM200, but the rates of hematologic response and of objective clinical improvement in amyloidrelated organ disease were significantly lower. The same group has tried to treat patients ineligible for HDM200 with two cycles of IDM 100 mg/m 2 . 16 Thirty patients were enrolled in this study. Only five of them could achieve the whole procedure with the double transplant program. The early mortality was 20% within the first 100 days after ASCT, and 43% of patients died with a median of 5 months after treatment. With a median follow-up of 24 months, over half of all patients were alive, including three of nine patients with predominant cardiac involvement who survived 2-3 years after treatment. This study highlights the fact that a double transplant program in patients with AL is very difficult to achieve, and raises the issue previously discussed of careful patient selection before ASCT.
Conventional therapy before ASCT?
It is unclear whether patients should receive chemotherapy before the conditioning regimen and ASCT or not. In at least two series of ASCT neither survival nor disease response were influenced by the fact or extent of any prior oral therapy. 6, 16 Patients who have received extended therapy with oral melphalan before ASCT are at risk of both poor stem cell collection and subsequent myelodysplasia or secondary leukemia. Comenzo et al 5 reported one case of secondary leukemia among 25 patients treated with ASCT. Eighteen months posttransplant this patient, a 61-year-old woman developed acute myelogenous leukemia with a complex karyotype including deletion of chromosome 7. She had received the largest amount of prior oral melphalan (672 mg) of all the patients. Some authors have suggested that the combination regimen of vincristine, adriamycin and dexamethasone (VAD) could be an interesting option with both clinical improvement and regression of amyloid on serial SAP scintigraphic studies. 7, 20 However in a series of 26 cases treated with VAD, two patients died of heart failure during treatment and the potential cardiotoxicity of adriamycin must be borne in mind. 7 Other adverse effects of VAD therapy include risks of exacerbation of neuropathy, sepsis and fluid retention. On the contrary, Sezer et al 20 recently reported a case of dramatic improvement of nephrotic syndrome due to AL after VAD and subsequent ASCT with HDM200. These authors considered that using VAD before starting HDT might improve the condition of patients and reduce transplant-related morbidity and mortality.
Conclusion
ASCT offers new hope for patients with AL. The critical issue is patient selection before high-dose therapy. Which patients are too disabled by the disease to be treated intensively? As mentioned by the Accredition Sub-Committee of the European Group for Blood and Marrow Transplantation, the role of ASCT for AL should be defined in the context of a clinical research protocol. 21 A prospective randomized study comparing ASCT with conventional oral chemotherapy is clearly needed.
